News: 2016

Collaboration with ii curso de andrología de la seen

October 2016.– The II Andrology Course, promoted by the Spanish Society of Endocrinology and Nutrition (SEEN), has been supported and sponsored by Rubió Laboratories, a company always committed to initiatives that contribute to knowledge sharing. The course has been well received by professionals and has had 17 Spanish and European speakers of recognized prestige, who have addressed subjects from different disciplines, such as endocrinology, urology, pediatrics and biology.

In this course, held in Madrid, the following thematic blocks have been addressed: testicular pathophysiology, management and care of the patient with adult hypogonadism, sexual development and function, male infertility and systemic diseases and reproductive dysfunction, as well as several clinical cases. To conclude, the course has been closed with a look to the future thanks to the presentation ‘Future perspectives of andrology’ by the president of the European Academy of Andrology (AEA), Csilla Krausz.

58th congress of the spanish society of endocrinology

October 2016– The Spanish Society of Endocrinology and Nutrition (SEEN) celebrated this year its 58th Spanish National Congress in the city of Malaga which has been attended by about 2000 endocrine across the country. The Congress, which has presented an interesting program of high scientific level, has revealed many relevant aspects of these specialist’s activity.

Laboratorios Rubió is actively working with KOLs and many members of this scientific society, since the endocrines prescribe some of its products, as they are the appropriate therapy for their patients.

Laboratorios Rubió, always looking to create areas for discussion and exchange of knowledge, has sponsored a presentation on the importance of testosterone: ‘The testicle, a key organ in the “cross-talk” between bone, muscle and cardiovascular health’, which has been given by Dr. Guillem Cuatrecasas, Endocrinologist of Teknon Medical Center in Barcelona investigator of several international studies.

Laboratorios rubió collaborate with la federación española del ictus to raise awareness about the gravity of the stroke disease

October 2016.- Laboratorios Rubió, committed to health and quality of life, collaborates with FEDERACIÓN ESPAÑOLA DEL ICTUS (FEI) to raise awareness about the consequences of the stroke disease and the need to prevent it.

For the World Stroke Day, the FEI has organized a traveling photo exhibition called “Historias de un Ictus” (Stroke Stories) which will visit several Spanish cities, from this month until the end of the year, with Laboratorios Rubió support.

The exhibition deals with the stories of four people of different ages and backgrounds, who have suffered a stroke, not from the perspective of the disease but through daily acts of personal growth. The incidence of this disease reflects the severity of this problem, since it is known that 1 in 6 people will suffer a stroke over their lifetime.

The specialists claim that the new test of determination of Lipoproteínas is already used in clinical practice

July 2016 -The specialists value the use of a technique called LIPOSCALE that analyzes the size and number of lipoproteins in cardiovascular screening.

“Until now, we did not have in the clinic of any tool, of any test or advanced test of determination of lipoproteínas; But recently a technology has been developed in Spain based on magnetic resonance spectroscopy of two dimensions that allows to analyze, through a relatively simple and exportable procedure to the clinic, the patient’s lipoprotein map, it is to be hoped that it will soon be available to clinicians”, said Dr. Jacinto Fernández Pardo, head of the Arterial Hypertension and Lipids Unit of the General University Hospital Reina Sofía of Murcia, during his speech at a panel on ‘Importance Of the size of lipoproteins in cardiovascular screening: from theory to clinical practice ‘, which took place during the XXIX National Congress of the Spanish Society of Arteriosclerosis (SEA) held in Granada last May.

Launch of new drug, testogel, in an event with medical professionals from different fields

June, 2016. The new drug, Testogel, a hydroalcoholic gel that is colourless and clear, containing 1% testosterone, was launched at an event organised by the Centre of Urology, Andrology and Reproductive Medicine in conjunction with Laboratorios Rubió. The event was attended by professionals from different fields, who were able to see the product’s characteristics first hand.

The aim was to raise the profile of the treatment of hypercholesterolaemia with resins to reduce cholesterol, which is related to the metabolic syndrome of patients with erectile dysfunction. The various professionals had the opportunity to discuss the most pressing topics in the field of urology, andrology, endocrinology and reproductive health.

A new predictive test will allow greater accuracy of cardiovascular risk.

May 2016 – This technology created from the use of nuclear magnetic resonance is called LIPOSCALE and is already being applied in many clinical studies on different pathologies.

A new predictive test “will allow better treatment, better estimation and greater precision of our patients’ cardiovascular risk,” said Dr. Ángel Díaz Rodríguez, coordinator of the Working Group of Lipids of the Spanish Society of Primary Care (SEMERGEN).

Dr. Díaz Rodríguez participated in the Mesa ‘Importance of the size of lipoproteins in the screening of cardiovascular risk: LIPOSCALE’, held in the framework of SEMERGEN Cardiovascular Conferences (Santander, from May 19 to 21, 2016), session in Which was also attended by doctors Nuria Amigó Grau and Vicente Pallarés Carratalá. This technology created from the use of nuclear magnetic resonance is called LIPOSCALE and is already being applied in many clinical studies on different pathologies.

Cystistat, an example for professionals working in radiation oncology

March, 2016 – Laboratorios Rubió, as part of its continuous dedication to research and promotion of scientific inquiry, was a driving force behind the conference “Current state of the prevention and treatment of acute and late toxicity in the pelvis. An original technique for radiation cystitis”, that was presented as part of the 8th Congress on Complementary Therapies in Radiation Oncology. This congress, held at Madrid’s Hospital de la Paz and attended by more than 250 professionals, offers a wide programme of high educational value, led by specialists Ana Mañas and Alejandro de la Torre.

The conference driven by Rubió was led by Dr Luis Olay, head of the prostate division of the radiation oncology service of the Hospital Universitario Central de Asturias (HUCA), who presented a real-life case of a patient undergoing radiation therapy treated with Cystistat, with a very good prognosis and progression. “We used Cystistat because of its molecular weight, efficacy and concentration, which make it the ideal hyaluronic acid for this technique. Not all hyaluronic acids are the same”, he stated in his presentation. The aim of the congress is to bring medical knowledge in radiation therapy up to date, in order to improve the quality of life of cancer patients, reduce the complications they suffer, and treat their long and short-term side effects.

Laboratorios rubió and incliva sign an agreement to jointly promote biomedical research

February, 2016 – Rafael Carmena and Carlos Rubió, General Directors of the INCLIVA Health Research Institute and Laboratorios Rubio respectively, signed a collaborative agreement in June whose aims include research, development, innovation, training and promotion of scientific inquiry in the field of biomedicine.

Both entities are aware of the importance of promoting and strengthening cooperation in technical, scientific, economic and educational aspects of the field, as a tool to spark the development of research and the economy.